S100A7 and breast carcinoma: Our in vivo findings concur with a previous study which reported that S100A7-downregulated tumors have reduced VEGF expression in vitro as compared to vector-transfected control cells, and that human breast cancer tissues with decreased S100A7 expression levels have reduced CD31 staining [14].